A

Advanced Research Center, Inc. | Anaheim, CA

Research site
(Unclaimed)
Location
1020 S. Anaheim Boulevard, Suite 316, Anaheim, California, United States of America
Site insights

Top conditions

Schizophrenia (10 trials)

Alzheimer Disease (6 trials)

Osteoarthritis (3 trials)

Constipation (3 trials)

COVID-19 (2 trials)

Top treatments

SEP-363856
KarXT
Troriluzole
Obeldesivir
SEP-4199
Tenapanor
Triamcinolone Hexacetonide
Tanezumab
Lorecivivint
BIIB092

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

16 of 34
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

A clinical study that will evalute how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their cur...

Active, not recruiting
Schizophrenia
Drug: SEP-363856

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Semagludtide
Drug: Placebo (semaglutide)

The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment d...

Enrolling
Attention Deficit Hyperactivity Disorder
Drug: Guanfacine hydrochloride (TAK-503)
Other: Placebo

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in d...

Active, not recruiting
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Enrolling
Schizophrenia
Drug: Placebo
Drug: iclepertin

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolesc...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant / BHV3000

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Invitation-only
Alzheimer Disease
Drug: Simufilam

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Invitation-only
Irritable Bowel Syndrome With Constipation (IBS-C)
Drug: Tenapanor

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling
Irritable Bowel Syndrome With Constipation (IBS-C)
Drug: Tenapanor 50 MG
Drug: Placebo

Trial sponsors

S

Sumitomo Pharma America, Inc. (6 trials)

Boehringer Ingelheim logo

Boehringer Ingelheim (3 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems